Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06087913 · ClinicalTrials.gov registry record · Phase 1
Safety and PK Multi-dose Study of TAF/EVG Vaginal Insert
A Phase 1 study, sponsored by Eastern Virginia Medical School.
- Completed
- Registry status
- Phase 1
- Development phase
- 68
- Enrollment target
NCT06087913: Completed Phase 1 study, sponsored by Eastern Virginia Medical School.
NCT06087913 is a Phase 1 study that has completed, run by Eastern Virginia Medical School. The registered enrollment target is 68 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (13% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06087913, a Phase 1 study, has completed, sponsored by Eastern Virginia Medical School.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 68 participants
- Enrollment target
Study Summary
MATRIX-001 will examine the safety, PK, modeled PD, and acceptability of inserts containing the combination of TAF and EVG applied vaginally, daily for 3 days, then every other day for 14 days. The inserts are ultimately intended to be the basis of an event-driven, on-demand method for prevention of HIV and HSV sexual infection.
Primary Outcome
Safety measured by reported AE's Grade 2 and higher
Interventions
- DRUG TAF/EVG vaginal insert
- DRUG Matching Placebo vaginal insert
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2023-11-08 |
| Est. Completion | 2024-12-02 |
| Phase | Phase 1 |
What the finished NCT06087913 record still lists
NCT06087913 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 68 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (13% higher).
The record links to 0 conditions, and to 2 interventions - of which TAF/EVG vaginal insert is the first listed.
NCT06087913 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06087913 about?
NCT06087913 is a clinical study titled "Safety and PK Multi-dose Study of TAF/EVG Vaginal Insert". MATRIX-001 will examine the safety, PK, modeled PD, and acceptability of inserts containing the combination of TAF and EVG applied vaginally, daily for 3 days, then every other day for 14 days. The inserts are ultimately intended to be the basis of an event-driven, on-demand method for prevention of...
What is the current status of trial NCT06087913?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 68 participants. The study started on 2023-11-08. Estimated completion is 2024-12-02.
What interventions are being tested in trial NCT06087913?
The interventions under investigation include: TAF/EVG vaginal insert (DRUG), Matching Placebo vaginal insert (DRUG).
Who is sponsoring clinical trial NCT06087913?
This trial is sponsored by Eastern Virginia Medical School, which has 36 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06087913's enrollment target sits among peer trials
68 776th of 2000 higher than 1,219 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02044497 · 68 participants · Phase 4
Population Pharmacokinetics and Pharmacogenomics of Oral Oxycodone in Pediatric Surgical Patients
- NCT03779854 · 68 participants · Phase 2
Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant
- NCT03821246 · 68 participants · Phase 2
Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy
- NCT04115514 · 68 participants · Phase 2
Treatment of ARDS With Instilled T3
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI